Background: It is in debate that which statin is preferable in patients with acute myocardial infarction. Also, clinical impacts of different statin according to lipophilicity are unknown. So, we investigated one-year clinical outcomes of different types of statin in patients with acute myocardial infarction. Methods: A total of 1,159 patients with acute myocardial infarction (AMI) were included in present study. All patients were prescribed statin before discharge and divided into two groups by lipophilicity of statin: Group I (hydrophilic statin; rosuvastatin, pravastatin, n = 331), Group II (lipophilic statin; atorvastatin, simvastatin, fluvastatin, pitavastatin, n = 828). End-points were in-hospital outcomes, major adverse cardiac outcomes (MACE; all cause of death, re-MI, re-percutaneous coronary intervention [PCI], and surgical revascularization), and all cause of deaths during one-year clinical follow-up. Results: Patients performed PCI with coronary stenting were 919 patients (91.3%). MACEs at one-year were occurred in 219 patients (19.1%). Baseline characteristics and cardiovascular risk factors were similar between both groups except history of cerebrovascular diseases (2.1% vs. 5.4%, p = 0.012). There is no significant difference in patients with ST-elevation MI (31.4% vs. 34.1%, p = 0.408). Among patients implanted coronary stents, length of stent were more longer in group II (23.7짹5.6mm vs. 24.6짹5.9mm, p = 0.016). Other angiographic findings, rate of implanted drug-eluting stents, and procedural success rate were similar between both groups. In-hospital complications including in-hospital mortality were not different in both groups (11.5% vs. 12.6%, p = 0.692; in-hospital mortality 0.9% vs. 0.7%, p = 0.720). Although MACEs at one-month, and six-months during clinical follow-up were more occurred in group I (one-month; 10.1% vs. 4.5%, p = 0.001, six-months; 20.6% vs. 13.9%, p = 0.007), there is no differences of MACEs and deaths at one-year follow-up period (22.2% vs. 17.9%, p = 0.113 and 8.9% vs. 6.1%, p = 0.093 respectively). In Cox-regression analysis, hydrophilic statin did not predict one-year MACEs (hazard ratio [HR] 1.21, 95% confidence interval [CI] 0.89 to 1.66, p = 0.226), and all-cause of deaths (HR 1.27, 95% CI 0.73 to 2.21, p = 0.406). Conclusion: Although short-term cardiovascular outcomes were more better in lipophilic statin in patients with AMI, long-term outcomes were not different between hydro- and lipophilic statin. KEY WORDS: Acute myocardial infarction; Statin